| 主权项 |
1. A method of treating a cardiovascular disorder in a subject, comprising:
providing an extracellular matrix (ECM) composition comprising acellular ECM, said acellular ECM comprising endogenous proteoglycans, transforming growth factor-β (TGF-β) and vascular endothelial growth factor (VEGF), said ECM composition further comprising an added growth factor selected from the group consisting of fibroblast growth factor-2 (FGF-2), basic fibroblast growth factor (bFGF), transforming growth factor-alpha (TGF-α), transforming growth factor-beta (TGF-β), and vascular epithelial growth factor (VEGF), wherein, when said ECM composition is administered to damaged cardiovascular tissue, said growth factor augmented ECM composition induces myofibroblast and stem cell migration, and differentiation of said stem cells into cardiomyocytes; providing a mechanical circulatory support (MSC) device that is configured to support ventricular function of a mammalian heart when connected thereto; connecting said MSC device to said subject's circulatory system; administering said ECM composition proximate damaged cardiovascular tissue of said subject's heart, wherein said ECM composition induces neovascularization and bioremodeling of said subject's damaged cardiovascular tissue; and providing support of ventricular function of said subject's heart with said MSC device. |
